Markets BTIG ups OncoCyte PT to $8 from $5 BTIG raised its price target for OncoCyte (NYSE American:OCX) to $8 from $5, citing a recent direct offering of $25-million with its two largest institutional shareholders, which gives the company “ammunition to execute... January 26, 2021